TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of 24 vs 48 Weeks of Pegetron® (Peginterferon Alfa-2b + Ribavirin) in Naïve Genotype 1 Hepatitis C (Study P05016)(TERMINATED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must demonstrate willingness to participate in the study.~* Diagnosed with chronic HCV.~* Between 18 and 65 years of age of either gender and of any race.~* a. HCV positive, \>600,000 IU/mL at baseline AND b. Genotype 1.~* Suitable for treatment with Pegetron® per the Canadian product monograph.~* Investigator has already decided to treat with PEGETRON REDIPEN®~1.5mcg/kg/week of peginterferon alpha-2b plus 800-1200 mg /day of ribavirin.~* HCV-RNA negative at treatment week 4.~* Meet certain minimum laboratory values at the week 4 screening visit.~* Women of childbearing potential and male partners must agree to use a medically accepted method of contraception prior to screening, while receiving protocol-specified medication, and for 6 months after stopping the medication. Acceptable methods of contraception include condoms (male or female) with or without a spermicidal agent, diaphragm or cervical cap with spermicide, medically prescribed IUD, oral or injectable hormonal contraceptive, and surgical sterilization (e.g. hysterectomy or tubal ligation).~Exclusion Criteria:~* Had previous interferon-based therapy for Chronic Hepatitis C.~* Active Hepatitis B virus (HBV) infection.~* Human Immunodeficiency Virus (HIV) antibody positive.~* Cirrhotic (Stage 4 on Metavir system).~* Uncontrolled history or current severe depression or psychoses.~* Uncontrolled epilepsy.~* Use of illicit drugs.~* History of non-compliance to medical regimens.~* Liver disease other than from chronic hepatitis C.~* Participating in any other clinical study.~* Used any investigational drugs within 30 days of screening.~* Participants weighing \< 40 kg or \> 125 kg.~* Pregnant women or women who plan to become pregnant or sexual partners of women who want to become pregnant.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Pegetron® - 24 Weeks (Type: EXPERIMENTAL): Participants are treated with Pegetron® (pegylated interferon alfa-2b and ribavirin) for 8 weeks and then randomized to an additional 16 weeks of treatment
- Pegetron®- 48 Weeks (Type: ACTIVE_COMPARATOR): Participants are treated with Pegetron® (pegylated interferon alfa-2b and ribavirin) for 8 weeks and then randomized to an additional 40 weeks of treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: N-Terminal Pro-brain Natriuretic Peptide Hormone and Persistent Pulmonary Hypertension

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* \>/= 34 weeks gestation at birth~* clinical diagnosis of PPHN~Exclusion Criteria:~* newborns with evidence of structural heart disease, congenital anomalies and prior use of inhaled nitric oxide.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 6 Months
- Healthy Volunteers: t

Study Arms:
- PPHN (Type: None): Infants with persistent pulmonary hypertension (PPHN)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Keppra for Neonatal Seizures

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* Gestational age ≥ 35 weeks~* Postnatal age ≤ 30 days~* Birth weight ≥ 2000 grams~* Clinical or electrographic seizures of any etiology requiring treatment with an antiepileptic medication (as per the judgment of the clinician caring for the patient)~* Parental consent obtained~Exclusion criteria:~* Infants with renal insufficiency indicated by serum creatinine \> 2.0 (as part of pre-screening, labs obtained as part of routine care will be reviewed. Infants who have not had a creatinine drawn will have one drawn as part of the study after consent is obtained. If the baby requires levetiracetam emergently before the results of the creatinine are back, the dose will still be given and levels will still be drawn as per the protocol.~* Infants who have previously received levetiracetam~* Parents refuse consent

- Gender: ALL
- Minimum Age: None
- Maximum Age: 30 Days
- Healthy Volunteers: f

Study Arms:
- Levetiracetam as first line (Type: None): Babies who receive levetiracetam as a first line drug for seizures
- Phenobarbital as first line (Type: None): Babies who receive phenobarbital as a first line drug for seizures and levetiracetam as a second line drug

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Prolonged Exposure to Doxorubicin in Patients With Glioblastoma Multiforme and Diffuse Intrinsic Pontine Glioma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females patients, aged \>3 years and \< 30 years;~* Newly diagnosed of GBM, DIPG, diffuse brainstem glioma, diffuse spinal glioma, bilateral thalamic glioma, gliomatosis cerebri, anaplastic astrocytoma;~* Patients undergone either surgery or biopsy only;~* No prior chemotherapy and/or radiotherapy;~* Life expectancy ≥ 4 weeks;~* Karnofsky/Lansky ≥ 40 %;~* Written informed consent obtained from the patient/parents or legal representative;~* Adequate hematological function (leucocyte ≥ 2.0 x 10\^9/l -Hemoglobin ≥ 10 g/dl - platelet ≥ 50 x 10\^9 /l);~* Adequate liver function (total bilirubin ≤ 2.5 x ULN - ALT/AST ≤ 5.0 x ULN);~* Adequate renal function (serum creatinine ≤ 1.5 x ULN);~* Adherence to trial treatment and compliance with the protocol~Exclusion Criteria:~* Any disease or condition that contraindicates the use of the study drug (es. serious mental retardation, brain palsy, congenital syndrome, cardiomyopathy)~* Prior anti-cancer therapy~* Pregnancy or breastfeeding~* Non adequate contraception

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 30 Years
- Healthy Volunteers: f

Study Arms:
- Doxorubicin (Type: EXPERIMENTAL): Patients are treated with Weller-Stupp protocol: initial radiotherapy (1.8 Gy/die, days 1-5; total dose 54-60 Gy) with concomitant oral temozolomide (75mg/m2/die, days 1-7) per 6 weeks.~At week 10 (4 weeks after the chemo-radiotherapy treatment completion): 1 cycle of oral temozolomide (150-180 mg/m2, days 1-5)~At week 14 (8 weeks after the chemo-radiotherapy treatment completion) 1 cycle of prolonged infusion of Doxorubicin (25mg/m2/die in 24 hours, days 1-4; total cumulative dose 100 mg/m2).~At week 18 (4 weeks after the end of doxorubicin administration): 16 cycles of oral temozolomide (initial dose of 150 mg/m2 increasing to 180 mg/m2 days 1-5, 28-day cycle).~Oral valproic acid (20-30 mg/Kg/die bid) is administered from week 1 until the last treatment day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Low Molecular Weight Heparin and Aspirin in the Treatment of Recurrent Pregnancy Loss: A RCT

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* history of two or more unexplained consecutive pregnancy losses prior to 32 weeks~* presence of one of the panel of autoantibodies/thrombophilia markers~* confirmed pregnancy~Exclusion Criteria:~* SLE~* known peptic ulcer disease~* sensitivity to ASA or heparin~* previous thrombotic event~* geographic distance from clinic~* failure to consent

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 44 Years
- Healthy Volunteers: f

Study Arms:
- a (Type: EXPERIMENTAL): None
- b (Type: ACTIVE_COMPARATOR): Low dose aspirin only

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Active Immunization of Patients With Carcinoma of Oral Cavity or Oropharynx With Autologous Dendritic Cells Transfected With DNA From Autologous Tumor

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~-~Written informed consent conforming to the institutional guidelines obtained from the patient.~Documented evidence of oral carcinoma or carcinoma of the oropharynx. Patients will undergo surgery, surgery and radiation or chemoradiation therapy, and will become eligible for the first vaccine between 1and 4 months after termination of conventional therapy.~Adequate immune competence, as indicated by positive reaction to one or more of the DTH skin tests.~Age 18 or above. Karnofsky performance status \> 70% and life expectancy \> eight months.~Adequate hematologic function:~Absolute neutrophil count \> 1,000/mm3 Absolute lymphocyte count \> 1,000/mm3 Hemoglobin \> 9 g/dl Platelets \> 100,000/mm3 h) Liver function tests: Bilirubin (total) \< 1.7 mg/dl Alkaline phosphatase \< 78 u/L (2 x ULN) SGOT \< 54 u/L (2 x ULN) Lactic dehydrogenase \< 180 u/L (2 x ULN) i) Kidney profile: Serum electrolytes Sodium 135-145 mEq/L Potassium 3.5-5.0 mEq/L Bicarbonate 21-28 mEq/L Chloride 100-108 mmol/L 2) Serum creatinine \<4.5 mg/dL (3 x ULN) 3) BUN 8-25 mg/dL j) At least four weeks since any prior radiation therapy, immunotherapy, or chemotherapy~Exclusion Criteria:~- One or more of the Inclusion Criteria are not met. A significant history or current evidence of cardiac disease including, but not limited to, congestive heart failure, coronary artery disease, angina pectoris, uncontrolled hypertension, serious arrhythmias; or myocardial infarction within the previous six months.~Evidence of active infection requiring antibiotic therapy. Positive HIV or Hepatitis B or C screen tests Active intracranial metastases. Previously resected intracranial disease and or previously irradiated intracranial metastases which have been stable for four weeks are eligible.~History of other concurrent malignancies except basal cell carcinoma, squamous cell carcinoma of the skin, or carcinoma in situ of the cervix.~Pregnant or lactating women. Patients requiring systemic corticosteroids (unless patient has had NO STEROIDS IN THE PAST 4 WEEKS).~Autoimmune disease including, but not limited to, rheumatoid arthritis, systemic lupus erythematous, multiple sclerosis, or ankylosing spondylitis

- Gender: ALL
- Minimum Age: 37 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dendritic Cells w/Tumor DNA (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Chemoembolization for Hepatocellular Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Patient factor~1. Age \> 18~2. Child-Pugh A or B cirrhosis~3. ECOG performance status Grade 2 or below~4. No serious concurrent medical illness~5. No prior treatment for HCC except for liver resection~6. Creatinine clearance \>55ml/min.~Tumor factor~1. HCC diagnosed by typical enhancement patterns on cross sectional imaging or histology.~2. Unresectable and locally advanced disease without extra-hepatic disease~3. Massive expansive tumor type with measurable lesion on CT~4. Total tumor mass \< 50% liver volume~5. Largest tumor of greatest dimension ≤ 15cm~Exclusion Criteria:~Patient factor~1. Serum creatinine level \> 130 umol/L~2. Presence of biliary obstruction not amenable to percutaneous drainage~3. Child-Pugh C cirrhosis~Evidence of impaired liver function~1. History of hepatic encephalopathy, or~2. Intractable ascites not controllable by medical therapy, or~3. History of variceal bleeding within last 3 months, or~4. Serum total bilirubin level \> 40 umol/L, or~5. Serum albumin level \< 30g/L, or~6. INR \> 1.3~Tumor factor~1. Presence of extrahepatic metastasis~2. Infiltrative lesion~3. Diffuse lesion~Vascular complications~1. Hepatic artery thrombosis, or~2. Partial or complete thrombosis of the main portal vein, or~3. Tumor invasion of portal branch of contralateral lobe, or~4. Hepatic vein tumor thrombus, or~5. Significant arterioportal shunt, or~6. Significant arteriovenous shunt

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TACE using a high dose of cisplatin (Type: OTHER): Two consecutive treatments at two months apart will be given. A delay in the second treatment is allowed if patients do not recover to an acceptable state for subsequent cycle of treatment. Two treatment sessions at one month apart may be required for each complete treatment to cover all lesions when the lesions are diffusely distributed and involving both lobes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Exparel Interscalene vs Indwelling Catheter

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* American Society of Anesthesia (ASA) 1, 2, and 3~* Ages 40-74~* Patients scheduled for total shoulder replacement~Exclusion Criteria:~* ASA 4 and 5~* Pre-existing pain disorder~* Regular consumption of chronic pain medication~* pregnant women~* any medical condition such as a clotting disorder~* anatomic abnormality that precludes use of an indwelling scalene catheter~* Body Mass Index (BMI) \>40~* Patient refusal~* Pre-existing diabetic neuropathy or Hemoglobin A1c \>9~* Failed block

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- Single shot Interscalene Nerve Block (Type: EXPERIMENTAL): This group will receive an interscalene nerve block. This will be administered as a single 20mL injection consisting of a mixture of 10mL of Exparel and 10mL of 0.5% bupivacaine hydrochloride.
- Indwelling Interscalene Catheter (Type: ACTIVE_COMPARATOR): This group will receive an indwelling interscalene catheter placed posterior to C5-C6 nerve roots (between the shoulders) and administered 15 mL of 0.5% ropivacaine plain for the block with no superficial cervical block. The On-Q pump will be set at a rate of 4 mL/hr.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Exercise Therapy With Risk Factor Management and Life Style Coaching After Vascular Intervention for Patients With Peripheral Arterial Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with peripheral arterial disease Rutherford stage 4 and 5, where it is possible to improve the vascularization of the affected leg with the help of an endovascular and / or open surgical vascular intervention.~* Patients with both legs are affected, but the most severe leg does not exceed stage 5.~Exclusion Criteria:~* Severe cardiopulmonary comorbidity (NYHA 4) and previous amputations of lower leg or thigh.~* Patients with limited amputation of the toes can participate.~* Insufficient understanding of the Dutch language.~* No physiotherapy insurance.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Supervised exercise therapy (Type: EXPERIMENTAL): Adequacy of initial therapy, Investigation degree of confusion and dementia, Preoperative preparation, Life-style coaching, Supervised Exercise therapy.
- Walking advice (Type: NO_INTERVENTION): Standard care and a oral walking advice.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Early Standardized Task-Specific Training (ESTT)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Recent stroke (less than 6 weeks)~* Able to give conformed consent or have family member who can give consent~* first time stroke OR complete recovery from prior stroke~Exclusion Criteria:~* non-ambulatory before onset of stroke~* bilateral stroke~* presence of severe cardiac problems~* other co-morbidities which would affect gait training (i.e. amputation, spinal cord injury, traumatic brain injury, etc.)~* recent myocardial infarct (within 4 weeks)~* any uncontrolled health condition for which exercise is contraindicated~* severe lower extremity joint disease/pathology that would interfere with gait training~* subjects with BMI greater than 40~* significant cognitive impairment~* age greater than 80 years or less than 16 years~* able to complete 5 or more full heel raises with the affected ankle in standing with the knee extended with no more than one or two fingers on support surface for balance

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- early standardized task training (Type: EXPERIMENTAL): Persons in the experimental group will receive ESTT (early standardized task specific training) for gait treatment after stroke.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Five Fraction SABR Dose Escalation for Early Stage Squamous Cell Carcinoma of the Lung

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria~1. Age ≥ 18 at time of consent.~2. Ability to provide written informed consent and HIPAA authorization.~3. Pathological diagnosis of squamous cell carcinoma of the lung.~4. Staging PET/CT (invasive mediastinal staging strongly encouraged but not required).~5. Tumors \< 7cm~6. Any location eligible for SBRT (including, but not limited to, peripheral, chest wall abutting and central tumors)~7. N0 M0 disease~8. Plan to undergo four or five fraction SABR~9. Baseline PFTs available within 6 months of treatment start or will be obtained prior to treatment start (no finding will exclude patient from enrollment in trial)~Exclusion Criteria~1. Previous radiation therapy to the lung per investigator discretion.~2. Inability to comply with treatment per investigator discretion.~3. Inability to follow standard of care follow up recommendations per investigator discretion.~4. KPS\<40

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phase 1/Dose Level 1 (Type: EXPERIMENTAL): 11 Gy will be given in 5 fractions for a total dose of 55 Gy
- Phase 1/Dose Level 2 (Type: EXPERIMENTAL): 12 Gy will be given in 5 fractions for a total dose of 60 Gy
- Phase 1/Dose Level 3 (Type: EXPERIMENTAL): 13 Gy will be given in 5 fractions for a total dose of 65 Gy
- Phase 1/Dose Level 4 (Type: EXPERIMENTAL): 14 Gy will be given in 5 fractions for a total dose of 70 Gy
- Phase 2 (Type: EXPERIMENTAL): The maximum tolerated radiation dose determined during Phase 1 (i.e. 11, 12, 13, or 14 Gy) will be given in 5 fractions for a total dose of 55, 60, 65, or 70 Gy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Ventricular Tachyarrhythmias Refractory To Shock With Beta Blockers: The SHOCK and BLOCK Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All patients age \> 18 years of age who develop an in-hospital VF or pVT arrest which persists after three or more precordial shocks.~* Patients who develop an in-hospital cardiac arrest due to asystole or PEA which subsequently converts to VF or pVT will be included.~Exclusion Criteria:~* Pediatric patients~* Pregnancy~* Age \< 18 years of age~* Patients who develop VF or pVT in the emergency room, operating room or surgical intensive care unit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard Of Care Drug Epinephrine (Type: ACTIVE_COMPARATOR): Additional doses of Epinephrine (1 mg) given as part of standard of care during cardiac arrest
- IV Metoprolol instead Epinephrine (Type: ACTIVE_COMPARATOR): IV metoprolol 5 mg. up to 2 times (only) during cardiac arrest will be given instead of additional Epinephrine doses

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues